Camptosar Reduced Starting Dose Recommended In Patients With Genetic Marker
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients with the deficiency of a metabolizing enzyme have an increased risk of neutropenia, revised labeling for Pfizer’s oncologic says. Patients with the deficiency should start at a lower dose, though the appropriate starting dose is not known, FDA says.